Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 8/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.34 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.34 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784072 | 1.00 | HDAC3 (0.38) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL10072445 | 0.92 | HDAC1 (0.40) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL1411073 | 0.87 | TAS1R3 (0.40) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL1411075 | 0.87 | TAS1R3 (0.40) | HDAC3HDAC1HDAC8HDAC6HDAC2 | |
| SCHEMBL1411066 | 0.80 | SLC6A19 (0.39) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL1411065 | 0.80 | SLC6A19 (0.39) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL1411363 | 0.79 | MAOB (0.50) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL1411360 | 0.79 | MAOB (0.50) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL9896765 | 0.78 | KDM4E (0.32) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL9896770 | 0.78 | KDM4E (0.32) | HDAC3HDAC1HDAC8HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2014-03-27 | — | — | US | disclosed |
| US-20130303576-A1 | ENZYME INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-11-14 | — | — | US | disclosed |
| US-20120149736-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2012-06-14 | — | — | US | disclosed |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | c/o Chroma Therapeutics Ltd. (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303576-A1 | ENZYME INHIBITORS | HDAC1, HDAC4, HDAC3 | HDAC3 3/4885HDAC1 1/4885HDAC8 13/4885 |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | HDAC3 2617/4885HDAC1 2824/4885HDAC8 2282/4885 |
| US-20140155439-A1 | ENZYME INHIBITORS | HDAC4, HDAC1, HDAC3 | HDAC3 3/4885HDAC1 2/4885HDAC8 11/4885 |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | HDAC3 2617/4885HDAC1 2824/4885HDAC8 2282/4885 |
| US-20120149736-A1 | ENZYME INHIBITORS | HAT1, HDAC1, NAT1 | HDAC3 5/4885HDAC1 2/4885HDAC8 10/4885 |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | HDAC3 2617/4885HDAC1 2824/4885HDAC8 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.